Tandem Diabetes Care (TNDM) Short-term Investments (2013 - 2026)

Tandem Diabetes Care (TNDM) has reported Short-term Investments for 14 consecutive years, with $393.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Short-term Investments rose 56.49% year-over-year to $393.2 million; the trailing twelve-month figure through Jun 2026 stood at $393.2 million (up 56.49% YoY), and the FY2025 full-year result was $202.0 million, down 45.26% from the prior year.
• Short-term Investments rose to $393.2 million in Q2 2026 per TNDM's latest filing, from $390.9 million in the prior quarter.
• Across five years, Short-term Investments topped out at $541.7 million in Q1 2022 and bottomed at $202.0 million in Q4 2025.
• Historically, Short-term Investments has averaged $387.4 million across 5 years, with a median of $398.9 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Short-term Investments tumbled 46.46% in 2025, then soared 56.49% in 2026.
• Over 5 years, Short-term Investments stood at $444.4 million in 2022, then fell by 7.95% to $409.0 million in 2023, then fell by 9.77% to $369.1 million in 2024, then plunged by 45.26% to $202.0 million in 2025, then jumped by 94.61% to $393.2 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $393.2 million, $390.9 million, and $202.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.